original ) (raw )Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease Patients: The SUSTAIN Study
ruth de francisco
Inflammatory Bowel Diseases
View PDFchevron_right
P629 Long-term effectiveness and safety of ustekinumab (UST) in patients with active Crohn’s disease (CD) in real life: Interim analysis of the SUSTAIN study
Santiago García-lópez
Journal of Crohn's and Colitis, 2020
View PDFchevron_right
Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience
P. Michetti
Alimentary pharmacology & therapeutics, 2018
View PDFchevron_right
Long-Term Clinical Effectiveness of Ustekinumab in Patients With Crohn’s Disease: A Retrospective Cohort Study
Satoshi Motoya
Crohn's & Colitis 360
View PDFchevron_right
Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates
Marc Ferrante
Journal of Crohn's and Colitis, 2019
View PDFchevron_right
Ustekinumab for Crohn’s disease: a nationwide real-life cohort study from Finland (FINUSTE)
Heikki Nuutinen
Scandinavian Journal of Gastroenterology, 2019
View PDFchevron_right
Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn’s disease: results from the ENEIDA registry
ruth de francisco
Alimentary Pharmacology & Therapeutics, 2019
View PDFchevron_right
Ustekinumab dose escalation improves clinical responses in refractory Crohn’s disease
Mohammed Abdelsalam
Therapeutic Advances in Gastroenterology, 2020
View PDFchevron_right
Predictors of Ustekinumab Failure in Crohn’s Disease After Dose Intensification
Sanchit Gupta
Inflammatory Bowel Diseases, 2020
View PDFchevron_right
Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn’s disease: A multicenter Israeli study
Nitsan Maharshak
United European Gastroenterology Journal, 2020
View PDFchevron_right
Effectiveness and safety of ustekinumab in bio-naïve Crohn’s disease patients: a multicentre observational retrospective study
Teresa Valdés Delgado
Therapeutic Advances in Gastroenterology
View PDFchevron_right
Effectiveness and Safety of Ustekinumab for Moderate to Severely Active Crohn’s Disease: Results from an Early Access Program in Brazil
Cyrla Zaltman
Journal of Clinical Medicine
View PDFchevron_right
Ustekinumab induction and maintenance therapy in refractory Crohn's disease
William Sandborn
View PDFchevron_right
Ustekinumab in Crohn’s disease: evidence to date and place in therapy
Tal Engel
Therapeutic Advances in Chronic Disease, 2016
View PDFchevron_right
Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab – A prospective, multicenter cohort from Hungary
Tamás Szamosi
Digestive and Liver Disease, 2022
View PDFchevron_right
Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn’s Disease
Marie Truyens
Clinical Gastroenterology and Hepatology, 2020
View PDFchevron_right
Ustekinumab in Crohn’s Disease Management: A Brazilian Observational Study
rodrigo bremer
Arquivos de Gastroenterologia
View PDFchevron_right
Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn’s Disease
Romain gerard
Digestive Diseases and Sciences, 2019
View PDFchevron_right
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
Ursula Seidler
The New England journal of medicine, 2016
View PDFchevron_right
Ustekinuma b for Crohn’s Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study
Marieke Pierik
Journal of Crohn's and Colitis, 2021
View PDFchevron_right
P505 Real-world short-term effectiveness of ustekinumab in Crohn’s disease: Results from the ENEIDA Registry
ruth de francisco
Journal of Crohn's and Colitis, 2019
View PDFchevron_right
Ustekinumab for the Treatment of Refractory Crohnʼs Disease
Valle García-sánchez
Inflammatory Bowel Diseases, 2016
View PDFchevron_right
An Australian Real-World Study of Treatment Persistence of Ustekinumab in Crohn’s Disease
Andrea Puig
Biologics: Targets and Therapy, 2021
View PDFchevron_right
The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn's Disease
Long Gao
Journal of Crohn's & colitis, 2018
View PDFchevron_right
Ustekinumab Tissue and Serum Levels in Patients With Crohn’s Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction
Lindsey Oudijk
Inflammatory Bowel Diseases, 2022
View PDFchevron_right
Intravenous Ustekinumab Reinduction Is Effective in Prior Biologic Failure Crohn’s Disease Patients Already on Every-4-Week Dosing
Rocío Sedano
Clinical Gastroenterology and Hepatology, 2021
View PDFchevron_right
Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence
Tal Engel
Digestive and Liver Disease, 2019
View PDFchevron_right
A nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn’s disease patients in Finland
Heikki Nuutinen
Scandinavian Journal of Gastroenterology, 2021
View PDFchevron_right
Su1971 REAL-WORLD EFFECTIVENESS AND SAFETY OF USTEKINUMAB FOR THE TREATMENT OF CROHNS DISEASE: THE SCOTTISH USTEKINUMAB COHORT
jonathan macdonald
Gastroenterology, 2020
View PDFchevron_right
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
William Sandborn
View PDFchevron_right